Table 1 Baseline characteristics of study patients.

From: Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer

Characteristics

Total (N = 231)

Age, median (range)

66 [37–86]

 < 65

108 (46.8%)

65–74

76 (32.9%)

 ≥ 75

47 (20.4%)

Sex (%)

Male

186 (78.5%)

ECOG (%)

0

40 (17.2%)

1

132 (56.9%)

 ≥ 2

60 (24.8%)

Smoking (ever) (%)

183(79.6%)

Stage

IV

231 (100%)

EGFR activating mutation (%)

24 (9.9%)

Tumor histologic type (%)

Adenocarcinoma

125 (54.1%)

Squamous

56 (24.2%)

Other NSCLC

50 (21.6%)

PD-L1 expression level (%)

 ≥ 1%

182 (78.8%)

Line of ICIs used (%)

1st

40 (17.3%)

2nd

73 (31.6%)

3rd or more

118 (51.1%)

Type of ICIs (%)

Nivolumab

174 (75.3%)

Pembrolizumab

54 (23.4%)

Atezolizumab

3 (1.3%)

Objective response (OR) (%)

70 (30.3%)

Progression (%)

138 (59.7%)

PLC, /µL

Pre-treatment, median [IQR]

1525.9 [1041.9–2070]

Post-treatment, median [IQR]

1676.7 [1178.6–2190]

  1. OR, partial response and complete response; PLC, peripheral lymphocyte count.
Back to article page